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Abstract
Aim
Natriuretic peptides are not only involved in cardiovascular adaption to various conditions, but also in metabolic diseases. We
performed this study to assess the effect of a very short time of lifestyle inpatient intervention on NTproBNP values in normotensive
subjects with severe obesity and normal cardiac function.
Methods
We recruited 14 consecutive obese normotensive subjects with normal cardiac function who were aged 30 years and more and
were referred to inpatient rehabilitation in an academic clinic over a two months period. They were examined at baseline and after a
3-weeks program including dietary intervention with hypocaloric diet and assisted personalized physical aerobic and anaerobic
activities and compared to age, sex and BMI-matched control subjects under usual care.
Results
BMI significantly decreased (40.8 ±1.6 vs 42.3 ± 1.6 kg/m , p <0.0001). Median reduction in body weight was 4.9 kg (interquartile
range 2.4–5.2 kg). After diet and exercise-induced weight loss, plasma NTproBNP levels showed an almost two-fold increase,
which was statistically significant (28.2 ± 12.3 vs 17.2 ± 13.2 ng/L, p = 0.01), and particularly relevant in the subgroup with NT-
proBNP values below median values compared to those with higher values (p = 0.02). No significant variations were found in
control subjects (18.0 ± 13.0 vs 16.5 ± 11.2 ng/L, p = 0.18). The lipid profile was significantly ameliorated, and both HbA1c and
insulin levels showed a marginally non-significant decrease after treatment.
Conclusions
An almost two-fold increase in NTproBNP levels was evident after a very short time period of lifestyle intervention in normotensive
severe obese patients without cardiac disease. This finding might have clinical relevance, considering the role of NT-proBNP as risk
factor of impaired glucose tolerance.
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Introduction
B-type natriuretic peptide (BNP) belongs to the family of the natriuretic peptides [1]. Stress of the ventricular wall due to volume
and/or pressure overload is the main inducer of BNP transcription [1] and BNP plays a key role in cardiovascular homeostasis,
counteracting the deleterious effects of cardiac overload and exerting anti-fibrotic and anti-hypertrophic effects in the heart [2]. The
active peptide BNP is released in equimolar concentrations with the inactive fragments NT-proBNP, which has a longer plasma half-
life, and both BNP and NT-proBNP are well-established diagnostic/prognostic biomarkers of heart failure [3] and independent
predictors of cardiovascular mortality [4–6].
Obesity is associated with cardiovascular diseases; however, BNP and NT-proBNP levels are paradoxically reduced in obese
subjects and a negative linear relationship between body mass index (BMI) and both BNP and NT-proBNP levels has been
consistently reported in epidemiological studies [7–9]. Recently, this inverse association has been also confirmed in morbid obese
subjects [10]. In addition, low levels of NT-proBNP are a strong predictor of type 2 diabetes onset. Indeed, a prospective cohort
study has shown that lower NT-proBNP values were associated with higher risk of incident type diabetes over a 12-years follow-up
period, independently of confounders and risk factors [11] and a common genetic BNP variant (rs198389), which results in a 20%
increase in plasma BNP levels, was found associated with a 15% reduced risk of diabetes [12]. The underlying cause of the relative
BNP deficiency in obese insulin-resistant subjects (natriuretic handicap) is not entirely known, but both a reduced synthesis/release
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from the heart and an enhance clearance thought the type C natriuretic peptide receptor have been implicated [13–15]. Regardless
of the mechanism, this natriuretic handicap is of high clinical relevance as it may expose obese patients to enhanced
cardiovascular risk. Moreover, there is emerging evidence that natriuretic peptides play a direct role in the control of metabolic
processes by enhancing lipolysis and energy expenditure [13,16]. Therefore, low BNP levels may be not only a consequence, but
also a cause/contributing factor in obesity.
There is relatively little information on the effect of body weight loss on circulating NT-proBNP levels. After gastric bypass surgery,
BNP was reported to increase and to correlate with weight reduction [17,18]. Data on the effect of weight loss following lifestyle
intervention are more conflicting and both increased and reduced NT-proBNP levels have been reported [19–21]. Therefore, it is of
interest to assess whether natriuretic peptide levels may vary after a short-term dietary and physical program in obese people
without other comorbidities. In this study, we assessed the effect of a short-time lifestyle inpatient intervention on NT-proBNP values
in normotensive subjects with severe obesity and normal cardiac function.
Materials and methods
The study recruited 14 consecutive subjects aged ≥30 years with body mass index (BMI)≥ 30 kg/m  who were referred over a two
months period to the Italian Auxologic Institute (Verbania, Italy) for inpatient rehabilitation. Patients were excluded if they had
hypertension, diabetes, chronic heart failure, cardiac valvulopathy, cirrhosis, chronic obstructive pulmonary disease, cancer and
estimated glomerular renal function < 60 ml/min/1.73m . All subjects were examined at baseline and after a 3-weeks inpatient
program including a dietary intervention with hypocaloric diet, and assisted personalized physical activities (aerobic and anaerobic).
We also examined an age (±5 years), sex and BMI (±5 kg/m ) matched control group of 14 subjects who were referred to the
outservice clinic for severe obesity of the Turin University Hospital, both at the first referral visit and after 3-weeks. They received
written dietary advice by a dietitian at the baseline visit only. All individuals gave written informed consent and the study was carried
out in accordance with the Declaration of Helsinki. The study was approved by the Ethical Committee of Turin University.
Anthropometric measurements (BMI, waist circumpherence and body composition) were assessed using standardized methods by
two medical researchers. Fat mass and fat-free mass were determined by bioelectrical impedance (BIA 101, Akern, Florence, Italy).
Blood pressure was measured using an aeroid sphygmomanometer. All laboratory measurements were centralized. Venous blood
samples were collected after at 8.00 a.m. after overnight fasting and at least for 20 min resting in supine position for determination
of creatinine, glycaemia, insulin, total and HDL-cholesterol, triglycerides and uric acid. LDL-cholesterol was calculated using the
Friedewald’s formula. An electro-chemiluminescent immunoassay (ECLIA, Roche Diagnostics International, Rotkreuz, Switzerland)
was used to measure levels. All patients performed at baseline ECG and a M-mode two-dimensional echocardiography (Sonos
2500; Hewlett-Packard) to recruit only asymptomatic subjects with normal cardiac rhythm and left ventricular systolic function.
Variables distributed normally are presented as mean and standard deviation (SD). Comparisons were performed using the paired
Student t test and the χ  test as appropriate. The sample size provided a power of 92% (a = 0.05) to detect a difference in NT-
proBNP of at least 85% of a standard deviation between baseline to the follow-up examinations. Linear linear regression was
performed to assess the association between NTproBNP, BMI and weight reduction. All P values were 2-sided, and P values of
less than 0.05 were considered statistically significant. STATA version 10.0 was used for the analyses.
Results
The study group (n = 14) had a mean age of 37.4 (± 12.1) years, a predominance of women (M/F 4/10), and various grade of
obesity with a BMI ranging from 34.1 to 55.0 kg/m . All patients were asymptomatic and left ventricular systolic function was normal
(ejection fraction 61.0 ± 4.5%). As shown in Table 1, the intervention was effective in reducing body weight [median body weight
reduction: 4.9 kg (interquartile range 2.4–5.2 kg)], BMI, and waist circumference. There were no significant changes in body
composition and blood pressure, while lipid profile was significantly ameliorated. Both HbA1c and insulin levels showed a
marginally non-significant decrease after treatment.
Table 1. Anthropometric and metabolic values at baseline and after a 3 weeks period treatment.
https://doi.org/10.1371/journal.pone.0181212.t001
Baseline mean plasma NT-proBNP levels were 17.2 ± 13.2 ng/l. After diet and exercise-induced weight loss, there was a significant
twofold increase in plasma NT-proBNP levels (28.2 ± 14.4 vs 17.2 ± 13.2 ng/L, p = 0.01) (Fig 1).
Fig 1. NTproBNP plasma values (ng/L) at baseline and after a 3 weeks period treatment.
https://doi.org/10.1371/journal.pone.0181212.g001
The increase was particularly relevant in people who had NT-proBNP levels at or below the detection level of 5 ng/L (n = 5).
Compared to obese people who had NTproBNP levels above the median value (13.0 ng/L), those who had lower levels showed the
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highest increase after lifestyle intervention (19.1 ± 14.1 ng/L vs 2.9 ± 8.5 ng/L, p = 0.02).
In the control group (n = 14, BMI = 122.3 ± 18.3 kg/m ), no significant variations in NT-proBNP levels were found over time (18.0 ±
13.0 vs 16.5 ± 11.2 ng/L, p = 0.18).
In linear regression, NTproBNP and BMI after weight loss were not significantly associated (β = 1.01, p = 0.11). Similarly, no
association was evident between NT-proBNP values measured at baseline and after weight loss (β = 0.31, p = 0.24) and between
Δ weight and ΔNT-proBNP (β = -2.13, p = 0.43).
Discussion
This study provides the original evidence that weight reduction after a short period of lifestyle intervention in normotensive severe
obese patients without cardiac diseases and other comorbidities was associated with an almost two-fold significant increase in
circulating NT-proBNP levels. This finding is clinically relevant in the light of recent evidence that low levels of natriuretic peptides
are strong independent predictors of progression from normal to impaired glucose tolerance [11–12]. In this context, results of our
study, although limited by the cross-sectional study design, suggest that the increase in NT-proBNP plasma levels might be a
marker of a parallel reduction in metabolic risk of these subjects. Indeed, a parallel tendency towards improvement in plasma levels
of Hba1c, insulin and lipids was also found, due to an almost 5 kg weight reduction obtained during a 3-weeks of intensive
treatment in the setting of a regional specialized clinic devoted to severe obese subjects. However, only prospective studies
assessing incidence of cardiovascular mortality in people with increased values of NT-proBNP after lifestyle intervention might
provide a definite conclusion on this issue.
Our finding of a short-term temporal relationship between NT-proBNP plasma levels and weight reduction is consistent with
previous studies examining the sustained association between weight loss and natriuretic peptides in different contexts. In a
prospective cohort of 131 obese subjects who underwent a three-months lifestyle intervention, significant increases in BNP were
found and change in BMI were related to change in BNP [17]. The study, however, recruited an heterogeneous group of high-risk
obese subjects, having either coronary heart disease or three and more risk factors, including diabetes, and results might have
been biased by confounders. By contrast, in our study inclusion criteria were very stringent and only asymptomatic normotensive
obese patients without other comorbidities, such as diabetes and cardiopulmonary diseases, were included. Another study
confirmed the effect of changes in body weight with one year dietary intervention on natriuretic peptides [18]. By contrast, a small
study found decreased concentrations of natriuretic peptides after hypocaloric diet in obese patients with essential hypertension
[22].
Two other studies examined the sustained effect of weight decrease obtained through bariatric surgery on NT-proBNP levels
[18–19]. In the first one, an increase in NT-proBNP values was evident in 132 obese subjects at two postoperative time point (2 and
6 months), with a 3.4 and 5-fold increase in NT-proBNP levels at 12-months [18]. Similar results were found in the second study,
recruiting 98 obese subjects who underwent gastric bypass surgery, with an increase in BNP levels at each postoperative time
point (3, 6, 9 months) compared with preoperative values, up to a three-fold increase after one year [19]. Interestingly, in a one-year
non-randomized controlled clinical trial, the increase in NT-proBNP was higher in obese subjects who underwent gastric bypass
surgery compared to obese subjects treated with lifestyle intervention, and correlated significantly with changes in body weight [21].
In no previous study the increase in NT-proBNP was attributable to conditions that typically upregulate NT-proBNP secretion, such
as elevated blood pressure, cardiac hypertrophy, increased left ventricular filling pressures or ventricular dysfunction, whereas
evidence is emerging on the metabolic roles played by natriuretic peptides in obesity and diabetes development [13]. Indeed, the
cardiac endocrine response is the integrated resultant of several pathophysiological interactions, which are even more complex in
obese subjects and not yet fully elucidated [14]. In spite of the cardiac overload, NT-proBNP and BNP levels are paradoxically
reduced in obese subjects and relative natriuretic peptide deficiency has been hypothesized to be involved in the increased
cardiovascular risk of obese subjects (the natriuretic handicap) [10,14, 22]. Adipose tissue expansion, a hallmark of obesity, is
linked to chronic low-grade inflammation and increased secretion of adipokines which increase insulin-resistance [13]. On the other
hand, hyperinsulinemia may contribute to lower levels of natriuretic peptides by up-regulating natriuretic peptide clearance receptor
(NPRC) expression in subcutaneous fat tissue [23]. Adipose tissue lipolysis is strongly regulated by insulin (antilipolytic) and
catecholamines (lipolytic). More recently, it has been found that natriuretic peptides, including BNP, have lipolytic activity also [13,
24]. Visceral fat expansion can increase the clearance of active natriuretic peptides by means of an increased expression of
clearance receptors on adipocytes, and in this way, it may contribute to decrease the activity of the cardiac endocrine system [14].
Impaired natriuretic peptide release has also been reported with a down-regulation of NPRA mRNA and protein level in fat tissue
and skeletal muscle in obesity [25]. In light of these observations, hyperglycemia and hyperinsulinemia may be the mechanisms
underlying natriuretic peptides deficiency in obesity and diabetes [26].
Limitation of our study should be considered. The sample size was quite limited, but the the study was designed to provide a power
of 90% and over to detect a significant variation in NT-proBNP levels over a short period of time. On the other side, we applied a
wide range of exclusion criteria, which allowed to limit the effect of confounders which might have biased results, such as
hypertension and cardiac hypertrophy. Cardiac function was assessed in all recruited subjects by ECG and transthoracic
echocardiography, and only asymptomatic subjects with normal cardiac rhythm and ejection fraction were enrolled. However, we
cannot exclude the possibility that patients with asymptomatic diastolic dysfunction were included, as this condition is frequent in
obese subjects and poorly detected by M-mode two-dimensional echocardiography (15). Echocardiography post intervention was
not performed, however it is unlikely that cardiac function have changed in a such short time period. Natriuretic peptides increase
after exercise, however blood samples were collected after overnight fasting, and it is unlikely this might have affected our results.
Finally, no subjects was treated with β-blockers-drugs, which might interfere with haemodynamic and lipolytic activities.
In conclusion, this study expands knowledge in this field showing an almost two-fold increase in NTproBNP levels after a very short
period of lifestyle intervention in normotensive severe obese patients without cardiac disease, which might have further clinical
implications, considering the role of NT-proBNP as risk factor of impaired glucose tolerance.
Supporting information
S1 File. The data underlying this study.
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